RAPT Therapeutics (RAPT) Announces Resignation of William Rieflin from Board

On January 3, 2025, William Rieflin resigned from the Board of Directors (the “Board”) of RAPT Therapeutics (NASDAQ: RAPT), effective immediately. Mr. Rieflin’s departure from the Board is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Mr. Rieflin will continue to serve as a consultant for the Company.

On January 5, 2025, the Board appointed Lori Lyons-Williams as Chair of the Board to succeed Mr. Rieflin. In connection with Mr. Rieflin’s departure, the Board resolved to reduce the size of the Board to six directors and appointed Linda Kozick as a member of the Audit Committee.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Home Depot expands executive roles, grants $500K in restricted stock
• Real and RE/MAX Holdings receive court approval for merger